Home LiteratureArticle Details
PMID: 37744351 Published · epublish English Clinical Trial Journal Article Research Support, Non-U.S. Gov't

Complement factor D regulates collagen type I expression and fibroblast migration to enhance human tendon repair and healing outcomes.

Frontiers in immunology ·Vol. 14 ·2023-00-00 ·页码 1225957

Chen J, Wang J, Hart DA, Zhou Z, Ackermann PW, Ahmed AS

Abstract

Dense connective tissues (DCTs) such as tendon, ligament, and cartilage are important stabilizers and force transmitters in the musculoskeletal system. The healing processes after DCT injuries are highly variable, often leading to degenerative changes and poor clinical outcome. Biomarkers in relation to repair quality for human DCTs, especially tendon are lacking. This study expands our previous findings and aimed to characterize the mechanisms by which a potential biomarker of good outcomes, complement factor D (CFD), regulates tendon healing. Quantitative mass spectrometry (QMS) profiling of tissue biopsies from the inflammatory phase of healing (n = 40 patients) and microdialysates from the proliferative phase of healing (n = 28 patients) were used to identify specific biomarkers for tendon healing. Further bioinformatic and experimental investigations based on primary fibroblasts and fibroblast cell line were used to confirm the identified biomarkers. The QMS profiling of tissue biopsies from the inflammatory phase of healing identified 769 unique proteins, and microdialysates from the proliferative phase of healing identified 1423 unique proteins in Achilles tendon rupture patients. QMS-profiling showed that CFD expression was higher during the inflammatory- and lower during the proliferative healing phase in the good outcome patients. Further bioinformatic and experimental explorations based on both inflammatory and proliferative fibroblast models demonstrated that CFD potentially improved repair by regulating cell migration and modulating collagen type I (Col1a1) expression. Moreover, it was shown that the enhanced Col1a1 expression, through increased fibroblast migration, was correlated with the validated clinical outcome. The results of the current studies characterized underlying inflammatory- and proliferative healing mechanisms by which CFD potentially improved tendon repair. These findings may lead to improved individualized treatment options, as well the development of effective therapies to promote good long-term clinical outcomes after tendon and other DCT injuries. http://clinicaltrials.gov, identifiers NCT02318472, NCT01317160.

Keywords
cell migration collagen type I complement factor D dense connective tissue patient outcome proteomics tendon rupture
MeSH 主题词
Humans Cell Movement Collagen Type I Complement Factor D Fibroblasts Tendons
化学物质
Collagen Type I Complement Factor D CFD protein, human
作者与单位
共 6 位作者,点击展开单位 / ORCID
Chen Junyu
Department of Orthopedics, Orthopedic Research Institute, West China Hospital of Sichuan University, Chengdu, Sichuan, China. | Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Wang Jin
The Key Laboratory of Tumor Molecular Diagnosis and Individualized Medicine of Zhejiang Province, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, China. | Department of Pharmacology, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi, China.
Hart David A
McCaig Institute for Bone & Joint Health, University of Calgary, Calgary, AB, Canada.
Zhou Zongke
Department of Orthopedics, Orthopedic Research Institute, West China Hospital of Sichuan University, Chengdu, Sichuan, China.
Ackermann Paul W
Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden. | Department of Trauma, Acute Surgery and Orthopaedics, Karolinska University Hospital, Stockholm, Sweden.
Ahmed Aisha S
Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Article Info
Journal
Frontiers in immunology
Abbr.
Front Immunol
ISSN
1664-3224
Published
2023-00-00
电子出版
2023-00-06
页码
1225957
Language
English
Country/Region
Switzerland
NLM ID
101560960
数据资源
ClinicalTrials.gov
NCT02318472, NCT01317160
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]